Association of Circulatory Iron Deficiency With an Enlarged Heart in Patients With End-Stage Kidney Disease

High prevalence of iron deficiency (ID) and cardiomyopathy have been observed in patients with end-stage kidney disease (ESKD). Our objective was to clarify associations between ID and cardiac remodeling in patients with ESKD.
Source: Journal of Renal Nutrition - Category: Urology & Nephrology Authors: Tags: Original Research Source Type: research

Related Links:

[Ghanaian Times] I have devoted the last few days to sharing information on diabetes. The feedbacks have been good. There was one that I would like to share with you, dear reader.Can diabetes on its own cause heart disease in a person? The response is yes. There is actually a condition known as diabetic cardiomyopathy.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Publication date: Available online 11 November 2019Source: Medicina Intensiva (English Edition)Author(s): I. Keituqwa Yáñez, S. Nicolás Franco, A. Arcís Conesa
Source: Medicina Intensiva - Category: Intensive Care Source Type: research
ConclusionMachine learning-based texture analysis of late gadolinium-chelate enhancement-positive areas is a promising tool for the classification of hypertrophic cardiomyopathy patients with and without VT.
Source: Diagnostic and Interventional Imaging - Category: Radiology Source Type: research
Source: Indian Journal of Pediatrics - Category: Pediatrics Source Type: research
RASopathies are a group of rare genetic diseases caused by germline mutations in genes involved in the RAS–mitogen-activated protein kinase (RAS-MAPK) pathway. Whole-exome sequencing (WES) is a powerful approach for identifying new variants in coding and noncoding DNA sequences, including miRNAs. miRNAs are fine-tuning negative regulators of gene expression. The presence of variants in miRNAs could lead to malfunctions of regulation, resulting in diseases. Here, we identified 41 variants in mature miRNAs through WES analysis in five patients with previous clinical diagnosis of RASopathies syndromes. The pathways, bio...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
ConclusionsREDUCE LAP-HF II is designed to evaluate the clinical efficacy of the IASD device in patients with symptomatic HF with elevated LA pressure and LVEF≥40%.
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 11 November 2019Source: American Heart JournalAuthor(s): Dan Yang, Connor Galen O'Brien, Gentaro Ikeda, Jay H. Traverse, Doris A. Taylor, Timothy D. Henry, Roberto Bolli, Phillip C. YangBackgroundMononuclear cells (MNCs) have been tested in clinical trials across multiple cardiovascular pathologies with mixed results. Major adverse cardiac events (MACE) and markers of cardiovascular capacity have been particularly challenging to interpret due to small size. This meta-analysis is aimed to assess the efficacy of MNC therapy in randomized clinical trials to identify the markers of efficiency...
Source: American Heart Journal - Category: Cardiology Source Type: research
CONCLUSIONS Hence, we concluded that the overexpression of LINC-PINT may exhibit inhibitory effects on the progression of cardiomyopathy and retinopathy among patients with type 2 diabetes. PMID: 31711064 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
This cohort study examines the association of cardiac resynchronization therapy with change in left ventricular ejection fraction (LVEF)among patients with chemotherapy-induced cardiomyopathy.
Source: JAMA - Category: General Medicine Source Type: research
Cardio-oncology has developed as a new field due to the proliferation of novel cancer therapies that not only have improved outcomes for some types of cancer, but also may lead to various cardiovascular toxicities. Older therapies, such as anthracyclines, are associated with cardiomyopathy as a result of myocyte death at the time of treatment, followed by cardiac remodeling in the years following completion of therapy, and eventually lead to heart failure (HF). In 2019, data are limited on the prevention and treatment of cancer treatment –associated cardiomyopathy, with most interventions extrapolated from general HF...
Source: JAMA - Category: General Medicine Source Type: research
More News: Cardiology | Cardiomyopathy | Heart | Iron | Nutrition | Urology & Nephrology